Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars
{{output}}
Introduction: In the era of immunotherapy, bevacizumab seems to be losing its place in NSCLC treatment algorithms. The aim of this work is to try to define the advantages and disadvantages of NSCLC treatment with bevacizumab in c... ...
